"Non-small cell had the technology, it worked, it was feasible. Small cell technology has been a little bit more difficult because it has to capture the state, not a genetic change. There are emerging innovative therapies. We have been able to engineer compounds to work for us and I think they hold a lot of promise, but I think we should still continue to focus on early detection, early detection, early detection. Ask your doctors, tell your friends to ask their doctors for CAT scan screening."
Learn about "Understanding and Advancing SCLC Care: Current Insights and Future Directions" from Sonam Puri, MD, Associate Member at Moffitt Cancer Center in this Expert Speaker video.
This video was recorded during the LiveLung Small Cell Lung Cancer meeting on January 14, 2024.
Subscribe to our YouTube channel and click the notification bell so you know when new educational lung cancer videos are available https://www.youtube.com/livelung
About the Speaker Sonam Puri, MD
Clinical Research Medical Director in the Department of Thoracic Oncology
Moffitt Cancer Center
Dr. Puri earned her medical degree from Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences in Rohtak, Haryana, India. She completed her Internal Medicine Residency at the University of Connecticut School of Medicine in Farmington, followed by a Hematology and Oncology Fellowship at Moffitt Cancer Center in Tampa, Florida.
Dr. Puri is an Associate Member at Moffitt Cancer Center and serves as the Clinical Research Medical Director in the Department of Thoracic Oncology. She also serves as the Co-Chair of the Thoracic Neuroendocrine Subcommittee at the Southwest Oncology Group. Dr. Puri is actively involved in several national and international professional organizations. She is a member of the National Comprehensive Cancer Network (NCCN) Small Cell Lung Cancer Clinical Practice Guidelines Committee, the American Society of Clinical Oncology's (ASCO) Evidence-Based Medicine and Thoracic Guideline Advisory Committee, the Southwest Oncology Group Lung Cancer Disease Working Group, and the International Association for the Study of Lung Cancer's (IASLC) Membership Committee. Dr. Puri’s clinical expertise lies in the treatment of thoracic malignancies, including non-small cell and small cell lung cancer. Her research interests center on designing and conducting clinical trials to explore immunotherapy, targeted therapies, and novel therapeutic strategies for patients with thoracic cancers.
The LiveLung Small Cell Lung Cancer Program is supported in-part by grants from AstraZeneca, Amgen, and Jazz Pharmaceutical.
This Video Content has been made available for informational and educational purposes only. The Video Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read or seen on the Site.
LiveLung and speakers hereby disclaim any and all liability to any party for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising directly or indirectly from any use of the Video Content, which is provided as is, and without warranties.